Foreign and mainland Chinese drug makers are fighting for a multibillion-dollar slice of the domestic weight-loss market by slashing prices by as much as 80 per cent, as China faces a worsening obesity crisis.
Competition in the sector, dominated by global pharmaceutical giants Novo Nordisk and Eli Lilly, intensified after both secured obesity-drug approvals in China in 2024. The landscape is set to shift further when the patent on Novo Nordisk’s semaglutide expires in March in China, opening…
Liberal MPs leave delegation to Taiwan to avoid confusion as Carney heads to China
...
Read moreDetails